Iovance engineers a patient's own immune cells into a personalized living drug to attack solid tumors like melanoma and cervical cancer.
Revenue reached USD 0.26B in 2025, but the company burns cash heavily—net income was USD -0.39B—so no business line yet pays the bills.
Its cell-therapy manufacturing process is complex and proprietary, but competitors like Bristol Myers Squibb and Adaptimmune are advancing similar T-cell therapies, eroding its first-mover edge.
Strong Buy (sector percentile 98) — value D, growth A-, profitability C+, momentum A, revisions A+. Updated daily, sector-relative, identical for every user.
Key events, in time order
Multiple sources confirm new high without company news, sentiment-driven
UBS raises PT to $7 from $4, keeps Neutral, Amtagvi revenue $91M
Regulatory milestone; NSCLC update expected 4Q26
第二季度总收入超过99百万美元，同比增长66%，环比增长39%，创历史新高。
Q1 2026 revenue grew approximately 45% year-over-year to $71 million, with Amtagvi revenue of $60 million increasing 38% year-over-year
None yet
None yet
Iovance Biotherapeutics ($IOVA) is experiencing positive price momentum, reaching new 52-week highs, indicating a bullish trend driven by recent performance.
Main discussion
Different voices
Increasing unusual put option volume: $MDLN $ROST $VIK $IOVA $AAP $EYPT $ARE $OWL $LOGI $POWL $FN
$IMMX Another portfolio winner pushing 52‑week highs — trimmed at $13.4+. And just yesterday, $IOVA printed fresh 52‑week highs as well 🙏🙏
Options with increasing option implied volatility: $MRNA $PURR $VICI $SAN $MRVI $ETHU $XRPC $IOVA $GMAB $ETHE $BITU $ETH $PGEN $BSOL $MSTY
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
